ľ�ϸ���Ӱ��

Clara Labonia

What did you research during your PhD?

“We aimed to investigate a novel therapeutic strategy for cardiac disease, with a particular focus on treating myocardial infarction—one of the leading causes of heart failure, and a major contributor to morbidity and mortality worldwide. This strategy involves using lipid nanoparticles (LNPs) to deliver messenger RNA (mRNA) directly to the heart. LNPs have already demonstrated safety and efficacy as mRNA delivery vehicles, most notably through their widespread use in the approved mRNA COVID-19 vaccines.

Our research explored the application of LNPs beyond vaccines, specifically for delivering therapeutic mRNA to the infarcted heart to promote tissue regeneration. We successfully established proof of concept for this approach in both mouse and pig models. These findings may help pave the way for future advances in the development of mRNA-based therapies for patients with heart disease.”

How do you look back on your time in Utrecht?

“I have loved Utrecht since the first day I set foot in the city. It offers a unique balance of the charm of a small town with the opportunities of a larger city, enriched by a vibrant scientific and academic environment thanks to the Utrecht Science Park and the ľ�ϸ���Ӱ�� Medical Center Utrecht (UMCU). During the years of my PhD, I had the opportunity to broaden my scientific expertise and grow as a biomedical researcher, while also forming lasting personal and professional relationships.”

What are your plans after this?

“After completing my PhD, I worked for one year as a scientist in formulation development at Ayuvant, a biotech spin-off from Utrecht ľ�ϸ���Ӱ��. I am currently transitioning into a more translational role, where I aim to further integrate my medical knowledge with my research expertise to contribute more directly to patient-centered applications”